GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for ACTIVE A

ACTIVE A

Official Title

Atrial Fibrillation Clopidogrel Trial with ASA for Prevention of Vascular Events

Status

Completed

Overview

To determine the efficacy of clopidogrel plus ASA versus ASA alone in patients with AF and with at least 1 risk factor for stroke who have a contraindication for other oral anticoagulation.

Study Design

Randomized, double-blind, efficacy study, placebo controlled superiority trial.

Primary Endpoint

Composite outcome of stroke, non-CNS systemic embolism, myocardial infarction or vascular death

Number of Patients

7555

Number of Sites

625

Number of Countries

33

Study Period

2003–2008

Principal Investigator

Stuart Connolly

Program Manager

Susan Chrolavicius

Research Coordinator

Heather Beresh, Laura Bonilla

Key Publications

  • Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012 Jan-Feb;28(1):95-101. doi: 10.1016/j.cjca.2011.08.112. Epub 2011 Oct 8.
  • ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J